['The antiatherogenic effect of conjugated linoleic acid (CLA) has been demonstrated in animal models. Although there are plenty of ', 'In this study, we assessed the impact of CLA supplementation on the levels of atherosclerosis markers - high-sensitivity C-reactive protein (hs-CRP) and asymmetrical dimethylarginine (ADMA).', 'Seventy-four adult female subjects with body mass index ≥25 kg/m', 'No significant differences were found in hs-CRP and ADMA levels before and after nutritional intervention between both groups. The changes in hs-CRP and ADMA concentration values (Δhs-CRP; ΔADMA median [interquartile range]) did not differ between subjects from the placebo (-0.1 [-0.8 to 0.3]; -0.02 [-0.12 to 0.14]) and CLA (0.2 [-0.7 to 0.9]; 0.04 [-0.14 to 0.13]) groups. The incidence of reduction of hs-CRP or ADMA concentration was not different in subjects of the CLA group compared to those of the placebo group (41.9% vs. 50%, relative risk [RR]=0.8387, 95% confidence interval [CI]=0.4887-1.4493, '] Does twelve-week-conjugated linoleic acid supplementation have no effects on the selected markers of atherosclerosis in obese and overweight women?